Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Angina Pectoris Treatment Market (2017-2025): By Drug Class & Geography - Research and Markets

Research and Markets
Posted on: 19 Sep 17

The "Global Angina Pectoris Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025" report has been added to Research and Markets' offering.

The angina pectoris treatment market was valued at USD 8790.93 Mn in 2017, and is expected to reach USD 12,589.6 Mn by 2025, expanding at a CAGR of 5.2% from 2017-2025.

According to American College of Cardiology, Chronic angina affects over seven million North Americans and despite optimal pharmacological and interventional therapies, 32% of these patients remain symptomatic from coronary artery disease (CAD). The market experts suggest that, various approaches have included new pharmacologic antianginal agents, interventional approaches, and therapeutic angiogenesis for treatment of angina pectoris. The beta adrenergic blockers are the first line drugs and the largest drug class segment in angina pectoris treatment market.

The major factors assisting growth of beta adrenergic blockers are the efficiency, fast onset of action, accessibility to patients and high patient compliance. A few drugs in phase III of clinical trials are observed as the most potential molecules in the angina pectoris treatment. These potential molecules are such as Dantonic/T89 (Tasly Pharmaceuticals, Inc.), Bococizumab (Pfizer, Inc.), and Alirocumab (Sanofi SA, Regeneron Pharmaceuticals). North America angina pectoris treatment market is the largest market globally due to factors such as Rising prevalence of angina pectoris, obesity in young population, sedentary lifestyle, and rising awareness related to early diagnosis of angina pectoris.

Key Market Movements:

  • Rising prevalence of angina pectoris due to sedentary lifestyle and obesity in young generation
  • High demand for target specific and tailored drugs for angina pectoris treatment
  • In developing countries from Asia Pacific and Latin America the awareness related to cardiovascular diseases in increasing

Companies Mentioned:

  • Abbott Laboratories Inc.
  • Astra Zeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Forest Laboratories Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 Angina Pectoris Treatment Market: Market Dynamics and Outlook

Chapter 4 Global Angina Pectoris Treatment Market, By Drug Class

Chapter 5 Global Angina Pectoris Treatment Market, By Geography

Chapter 6 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/pgm8kp/global_angina

View source version on businesswire.com: http://www.businesswire.com/news/home/20170919005858/en/

Business Wire
www.businesswire.com

Last updated on: 19/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.